Following the success of the inaugural 2021 event, SynBio Day 2022 will bring together researchers, industry partners, government representatives and investors to discuss the opportunities and challenges of applying synthetic biology solutions to tackle climate change and benefit our environment.
eureKARE launches synthetic biology studio network with inaugural biomedical studio in Belgium.
Georges Rawadi appointed eureKARE’s Chief of Biotech Studio Development.
It’s our one-year anniversary and we’re celebrating all the exciting events and milestones that took place.
eureKARE announces the successful IPO on Euronext Paris of eureKING, the first European SPAC1 in healthcare dedicated to biomanufacturing that has been co-founded by eureKARE.
This collaboration aims to complete NovoBiome’s disruptive NovoSift® ex-vivo research and discovery platform to analyze the symbiotic relationship between the microbiota and the human intestine.
DNA Script, a pioneer in Enzymatic DNA Synthesis (EDS) for on-demand DNA printing, today announced the completion of its Series C financing, raising $200 million of new capital. With this latest financing, DNA Script has raised $315 million since the company was founded in 2014.
